The demand for and volume of data from surveys, registers or other sources containing sensible information on persons or enterprises have increased significantly over the last several years. At the same time, privacy protection principles and regulations have imposed restrictions on the access and use of individual data. Proper and secure microdata dissemination calls for the application of statistical disclosure control methods to the data before release.
This book is intended for practitioners at statistical agencies and other national and international organizations that deal with confidential data. It will also be interesting for researchers working in statistical disclosure control and the health sciences.
The determination of sample size and the evaluation of power are fundamental and critical elements in the design of clinical trials. If the sample size is too small, important effects may go unnoticed; if the sample size is too large, it represents a waste of resources and unethically puts more participants at risk than necessary. Recently many clinical trials have been designed with more than one endpoint considered as multiple primary or co-primary, creating a need for new approaches to the design and analysis of these clinical trials. The book focuses on the evaluation of power and sample size determination when comparing the effects of two interventions in superiority clinical trials with multiple endpoints. Methods for sample size calculation in clinical trials where the alternative hypothesis is that there are effects on ALL endpoints are discussed in detail. The book also briefly examines trials designed with an alternative hypothesis of an effect on AT LEAST ONE endpoint with a prespecified non-ordering of endpoints.